Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
formyl peptide receptor 1 siRNA
- Development stage
- Preclinical
- Lead developer
- Ruijin Hospital
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intranasal
01
Overview
formyl peptide receptor 1 siRNA is a small interfering RNA (siRNA) therapeutic designed to silence the expression of formyl peptide receptor 1 (FPR1). In preclinical models of sepsis-associated encephalopathy (SAE), FPR1 was identified as a key driver of pro-inflammatory microglial polarization and neuroinflammation. To overcome blood-brain barrier (BBB) delivery challenges, researchers developed an intranasal delivery system utilizing piezoelectric short fibers loaded with FPR1-siRNA@MG1-LNPs. This system converts mechanical energy from respiratory airflow and nasal ciliary beating into a localized microelectric field, enabling the therapeutic genes to bypass the BBB via electro-responsive active migration. Silencing of FPR1 suppresses microglial pyroptosis, reduces the release of inflammatory mediators, mitigates neuronal injury, and ameliorates cognitive dysfunction.
- Other names
- formyl peptide receptor 1 small interfering RNAFPR1 siRNAFPR-1 siRNAFPR 1 siRNAFPR1-siRNAFPR-1-siRNAFPR 1-siRNAFPR1-siRNA@MG1-LNPs
02
Targets
AGO2 (Argonaute RISC catalytic component 2)FPR1 (Formyl peptide receptor 1)
Beyond the preview
Go deeper on formyl peptide receptor 1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on formyl peptide receptor 1 siRNA.